Agustos 2013
Anti-pankreatik antikor, anti-nötrofil sitoplazmik antikor ve antiSaccharomyces cerevisiae antikorlarinin inflamatuvar barsak hastaliklarindaki tanisal degeri ve hastalik aktivitesi ile iliskilerinin degerlendirilmesi
Evaluation of diagnostic values of anti-pancreatic antibody, anti-neutrophil cytoplasmic antibody (p-ANCA) and anti-Saccharomyces cerevisiae antibody (ASCA) in inflammatory bowel disease and their association with disease activity
- Ana Sayfa
- Sayılar
- Agustos 2013
- Anti-pankreatik antikor, anti-nötrofil sitoplazmik antikor ve antiSaccharomyces cerevisiae antikorlarinin inflamatuvar barsak hastaliklarindaki tani...
Özet
Giris ve Amaç:Inflamatuvar barsak hastaligi ile iliskili oldukça fazla serolojik belirteç tanimlansa da klinik sonuçlari etkileyen kanitlar sinirlidir. Bu çalismada anti-pankreatik antikor, p-ANCA ve ASCA’nin inflamatuvar barsak hastaliginin ayirici tanisindaki yeri ve hastalik aktivitesi ile antikorlar arasindaki iliskinin degerlendirilmesi amaçlanmistir. Gereç ve Yöntem:Inflamatuvar barsak hastaligi tanili 95 hasta (63 ülseratif kolit, 29 Crohn hastasi, 3 indetermine kolit) ve 65 saglikli kontrolden alinan serum örneklerinden indirekt immunofluorosan yöntemi ile otoantikor varligi arastirildi. Bulgular:Anti-pankreatik antikor sikligi, Crohn hastaliginda %6,9 (2/29), ülseratif kolitte %3,2 (2/63) olarak saptandi. Indetermine kolit ve kontrol grubunda anti-pankreatik antikor tespit edilmedi. Ülseratif kolit ve Crohn hastaligi arasinda anti-pankreatik antikor sikligi açisindan istatistiksel olarak anlamli fark bulunmadi. p-ANCA sikligi, ülseratif kolitte %46 (29/63), Crohn hastaliginda %13,8 (4/29), indetermine kolitte %66,6 (2/3), kontrol grubunda %4,6 (3/65) olarak bulundu. p-ANCA sikliginin ülseratif kolitte, Crohn hastaligina göre istatistiksel olarak anlamli oldugu saptandi. ASCA sikligi Crohn hastaliginda %34,5 (10/29), ülseratif kolit hastalarinda %7,9 (5/63), kontrol grubunda %3,1 (2/65) olarak bulundu. Indetermine kolit olgularinda ASCA saptanmadi. ASCA sikliginin Crohn hastaliginda, ülseratif kolite göre istatistiksel olarak anlamli oldugu görüldü. Anti-pankreatik antikor, p-ANCA ve ASCA varliginin inflamatuvar barsak hastaliginda hastalik aktivitesi ile iliskili olmadigi tespit edildi. Sonuç: Anti-pankreatik antikorun inflamatuvar barsak hastaligi ile iliskili olabilecegi ancak ayirici tanisinda tek basina yeterli olamayacagi sonucuna varilabilir. ASCA ve p-ANCA’nin inflamatuvar barsak hastaligi ayirici tanisinda yardimci testler olarak kullanilabilecegi, anti-pankreatik antikor için daha fazla çalismaya ihtiyaç oldugu söylenebilir
Abstract
Background and Aims:Although many serological markers associated with inflammatory bowel disease have been defined, the evidence that interacts with clinical results is limited. We aimed to evaluate the relevance of anti-pancreatic antibody, p-ANCA and ASCA in the differential diagnosis of inflammatory bowel disease and their correlation with disease activity. Materials and Methods:The presence of antipancreatic antibody, p-ANCA and ASCA was determined in indirect immunofluorescence assay of serum samples from 95 patients with inflammatory bowel disease (63 ulcerative colitis, 29 Crohn’s disease, 3 indeterminate colitis) and 65 healthy controls. Results:Anti-pancreatic antibody was present in 6,9% (2/29) in Crohn’s disease and 3,2% (2/63) in ulcerative colitis. Anti-pancreatic antibody was not detected in the indeterminate colitis and control groups. No statistical difference was found between ulcerative colitis and Crohn’s disease in terms of anti-pancreatic antibody incidence. p-ANCA was detected in 46% (29/63) in ulcerative colitis, 13,8% (4/29) in Crohn’s disease, 66,6% (2/3) in indeterminate colitis, and 4,6% (3/65) in the control group. pANCA was statistically higher in ulcerative colitis compared to Crohn’s disease. ASCA was present in 34,5% (10/29) in Crohn’s disease, 7,9% (5/63) in ulcerative colitis and 3,1% (2/65) in the control group. ASCA was not detected in the patients with indeterminate colitis. ASCA was statistically higher in Crohn’s disease compared to ulcerative colitis. It was found that anti-pancreatic antibody, p-ANCA and ASCA were not associated with disease activity in inflammatory bowel disease. Conclusions:We may conclude that anti-pancreatic antibody can be associated with inflammatory bowel disease, but it is not sufficient by itself for the differential diagnosis of inflammatory bowel disease. ASCA and p-ANCA may be helpful tools in the differential diagnosis of inflammatory bowel disease, but more studies are warranted for antipancreatic antibody
